Is there a placebo problem in antidepressant trials?

Current Topics in Medicinal Chemistry

Volumn 5, Issue 11, 2005, Pages 1077-1086

  Yang, Huaiyu ^a   Cusin, Cristina ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trial; Major depressive disorder (MDD); Sequential parallel design

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYDROCORTISONE; NEFAZODONE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; NEUROCHEMISTRY; PREDICTION; PSYCHIATRY; PSYCHOTHERAPY; REGRESSION ANALYSIS; REVIEW; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; CONTROLLED CLINICAL TRIALS; HUMANS; PLACEBOS; TIME FACTORS;

EID: 27744566213     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774297092     Document Type: Review

References (74)

1. Hrobjartsson, A.; Gotzsche, P. C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New Engl. J. Med. 2001, 344, 1594-1602.
2. Demitrack, M. A.; Faries, D.; Herrera, J. M.; DeBrota, D.; Potter, W. Z. The problem of measurement error in multisite clinical trials. Psychopharmacol. Bull. 1998, 34, 19-24.
3. Kirsch, I.; Sapirstein, G. Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication. Prevention & Treatment 1998, 1, Article 0002a.
4. Klein, D. F. Listening to meta-analysis but hearing bias. Prevention & Treatment 1998, 1, Article 0006c.
5. (AHCPR), A. f. H. C. P. a. R. Treatment of Depression - newer pharmacotherapies: summary, evidence/report/technology assessment number 7.; Agency for Health Care Policy and Research: Rockville, 1999.
6. Kirsch, I.; Moore, T. J.; Scoboria, A.; Nicholls, S. S. The Emperor's New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration. Prevention & Treatment 2002, 5, Article 23.
7. Walsh, B. T.; Seidman, S. N.; Sysko, R.; Gould, M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287, 1840-1847.
8. Stolk, P.; Ten Berg, M. J.; Hemels, M, E.; Einarson, T. R. Meta-analysis of placebo rates in major depressive disorder trials. Ann. Pharmacother. 2003, 37, 1891-1899.
9. Storosum, J. G.; Elferink, A. J.; van Zwieten, B. J.; van den Brink, W.; Huyser, J. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004, 37, 32-36.
10. Hooper, M.; Amsterdam, J. D. Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants. NCDEU 39th Annual Meeting: Boca Raton, FL, 1998.
11. Khan, A.; Leventhal, R. M.; Khan, S. R.; Brown, W. A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. 2002, 22, 40-45.
12. Khan, A.; Detke, M.; Khan, S. R.; Mallinckrodt, C. Placebo response and antidepressant clinical trial outcome. J. Nerv. Ment. Dis. 2003, 191, 211-218.
13. Kirsch, I. Specifying nonspecifics: Psychological mechanisms of placebo effects. The placebo effect: An interdisciplinary exploration; Harvard University Press: Cambridge, MA, 1997; pp. 166-186.
14. Fisher, S.; Lipman, R. S.; Uhlenhuth, E. H.; Rickels, K.; Park, L. C. Drug effects and initial severity of symptomatology. Psychopharmacologia 1965, 7, 57-60.
15. Frank, J. D. Persuasion and healing; Johns Hopkins: Baltimore, 1973.
16. Posternak, M. A.; Miller, I. Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups. J. Affect. Disord. 2001, 66, 139-146.
17. Coryell, W.; Akiskal, H. S.; Leon, A. C.; Winokur, G.; Maser, J. D.; Mueller, T. I.; Keller, M. B. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. Arc. Gen. Psychiatry 1994, 51, 405-410.
18. Khan, A.; Warner, H. A.; Brown, W. A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch. Gen. Psychiatry 2000, 57, 311-317.
19. Bielski, R. J.; Friedel, R. O. Prediction of tricyclic antidepressant response: a critical review. Arch. Gen. Psychiatry 1976, 33, 1479-1489.
20. Joyce, P. R.; Paykel, E. S. Predictors of drug response in depression. Arch. Gen. Psychiatry 1989, 46, 89-99.
21. Brown, W. A.; Dornseif, B. E.; Wernicke, J. F. Placebo response in depression: a search for predictors. Psychiatry Res. 1988, 26, 259-264.
22. Stewart, J. W.; McGrath, P. J.; Quitkin, F. M.; Harrison, W.; Markowitz, J.; Wager, S.; Leibowitz, M.R. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Arch. Gen. Psychiatry 1989, 46, 1080-1087.
23. Nierenberg, A. A. Predictors of response to antidepressants general principles and clinical implications. Psychiat. Clin. North America 2003, 26, 345-352.
24. Lasagna, L.; Mosteller, F.; von Felsinger, J. M.; Beecher, H. K. A study of the placebo response. Am. J. Med. 1954, 16, 770-779.
25. Schatzberg, A. F.; Kraemer, H. C. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol. Psychiatry 2000, 47, 736-744.
26. Brown, W. A. Placebo as a treatment for depression. Neuropsychopharmacol. 1994, 10, 265-269; discussion 271-288.
27. Brown, W. A.; Johnson, M. F.; Chen, M. G. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992, 41, 203-214.
28. Brown, W. A.; Dornseif, B. E.; Wernicke, J. F. Placebo response in depression: a search for predictors. Psychiatry Res. 1988, 26, 259-264.
29. Iosifescu, D. V.; Bankier, B.; Fava, M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr. Psychiatry Reports 2004, 6, 193-201.
30. Roy-Byrne, P. P.; Pages, K. P.; Russo, J. E.; Jaffe, C.; Blume, A. W.; Kingsley, E.; Cowley, D. S.; Ries, R. K. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2000, 20, 129-136.
31. Ribeiro, S. C.; Tandon, R.; Grunhaus, L.; Greden, J. F. The DST as a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry 1993, 150, 1618-1629.
32. Wilcox, C. S.; Cohn, J. B.; Linden, R. D.; Heiser, J. F.; Lucas, P. B.; Morgan, D. L.; DeFrancisco, D. Predictors of placebo response: a retrospective analysis, Psychopharmacol. Bull. 1992, 28, 157-162.
33. Small, G. W.; Hamilton, S. H.; Bystritsky, A.; Meyers, B. S.; Nemeroff, C. B. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Internat. Psychogeriat. 1995, 7 Suppl, 41-53.
34. Sullivan, M. D.; Katon, W. J.; Russo, J. E.; Frank, E.; Barrett, J. E.; Oxman, T. E.; Williams, J. W. Jr. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J. Am. Board of Family Practice 2003, 16, 22-31.
35. Fava, M.; Evins, A. E.; Dorer, D. J.; Schoenfeld, D. A. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychotherapy & Psychosomatics 2003, 72, 115-127.
36. Fava, M.; Rosenbaum, J. F. How to write a study protocol: A primer for the clinician. Research Designs and Methods in Psychiatry; Elsevier Science: Amsterdam, 1992; pp 297-305.
37. Peselow, E. D.; Sanfilipo, M. P.; Difiglia, C.; Fieve, R. R. Melancholic/endogenous depression and response to somatic treatment and placebo. Am. J. Psychiatry 1992, 149, 1324-1334.
38. Otto, M. W.; Nierenberg, A. A. Assay sensitivity, failed clinical trials, and the conduct of science. Psychotherapy & Psychosomatics 2002, 71, 241-243.
39. Khan, A.; Brodhead, A. E.; Kolts, R. L.; Brown, W. A. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J. Psychiatr. Res. 2005, 39, 145-150.
40. Khan, A.; Brown, W. A. The placebo enigma in antidepressant clinical trials. J. Clin. Psychopharmacol. 2001, 21, 123-125.
41. Robinson, D. S.; Rickels, K. Concerns about clinical drug trials. J. Clin. Psychopharmacol. 2000, 20, 593-596.
42. Frank, J. D,; Frank, J. B. Persuasion and healing: a comparative study of psychotherapy.; The Johns Hopkins University Press: Baltimore, MD, 1991.
43. Myers, E. D.; Calvert, E. J. Information, compliance and side-effects: a study of patients on antidepressant medication. Brit. J. Clin. Pharmacol. 1984, 17, 21-25.
44. Kraemer, H. C.; Pruyn, J. P.; Gibbons, R. D.; Greenhouse, J. B.; Grochocinski, V. J.; Waternaux, C.; Kupfer, D. J. Methodology in psychiatric research. Report on the 1986 MacArthur Foundation Network I Methodology Institute. Arc. Gen. Psychiat. 1987, 44, 1100-1106.
45. Hypericum Depression Trial Study. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002, 287, 1807-1814.
46. Mundt, J. C.; Kobak, K. A.; Taylor, L. V.; Mantle, J. M.; Jefferson, J. W.; Katzelnick, D. J.; Greist, J. H. Administration of the Hamilton Depression Rating Scale using interactive voice response technology. MD Computing 1998, 15, 31-39.
47. DeBrota, D. J.; Gelwicks, S, C.; Potter, W. Z. Same rater versus different raters in depression clinical trials. 42nd Annual NCDEU Meeting: Boca Raton, FL, 2002.
48. Zimbroff, D. L. Patient and rater education of expectations in clinical trials (PREECT). J. Clin. Psychopharmacol. 2001, 21, 251-252.
49. Quitkin, F. M.; Rabkin, J. G.; Ross, D.; Stewart, J. W. Identification of true drug response to antidepressants. Use of pattern analysis. Arc. Gen. Psychiatry 1984, 41, 782-786.
50. Quitkin, F. M. Methodology of measuring the efficacy of antidepressants. Psychopharmacol. 1992, 106 Suppl, S87-89.
51. Senn, S. Are placebo run ins justified? BMJ 1997, 314, 1191-1193.
52. Trivedi, M. H.; Rush, H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacol. 1994, 11, 33-43.
53. Lee, S.; Walker, J. R.; Jakul, L.; Sexton, K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depression & Anxiety 2004, 19, 10-19.
54. Faries, D. E.; Heiligenstein, J. H.; Tollefson, G. D.; Potter, W. Z. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J. Clin. Psychopharmacol. 2001, 21, 561-568.
55. Quitkin, F. M.; McGrath, P. J.; Stewart, J. W.; Ocepek-Welikson, K.; Taylor, B. P.; Nunes, E.; Delivannides, D.; Agosti, V.; Donovan, S. J.; Ross, D.; Petkova, E.; Klein, D. F. Placebo run-in period in studies of depressive disorders. Clinical, heuristic and research implications. Br. J. Psychiatry 1998, 173, 242-248.
56. Evans, K. R.; Sills, T.; Wunderlich, G. R.; McDonald, H. P. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? J. Psychiatr. Res. 2004, 38, 437-444.
57. Leuchter, A. F.; Cook, I. A.; Witte, E. A.; Morgan, M.; Abrams, M. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry 2002, 159, 122-129.
58. Mayberg, H. S.; Silva, J. A.; Brannan, S. K.; Tekell, J. L.; Mahurin, R. K.; McGinnis, S.; Jerabek, P. A. The functional neuroanatomy of the placebo effect. Am. J. Psychiatry 2002, 159, 728-737.
59. Barbui, C.; Hotopf, M. Forty years of antidepressant drug trials. Acta Psychiatrica Scandinavica 2001, 104, 92-95.
60. Posternak, M. A.; Zimmerman, M. Is there a delay in the antidepressant effect? A meta-analysis. J. Clin. Psychiatry 2005, 66, 148-158.
61. Montgomery, S. A. Are 2-week trials sufficient to indicate efficacy? Psychopharmacol. Bull. 1995, 31, 41-44.
62. Stahl, S. M.; Nierenberg, A. A.; Gorman, J. M. Evidence of early onset of antidepressant effect in randomized controlled trials. J. Clin. Psychiatry 2001, 62 Suppl 4, 17-23; discussion 37-40.
63. Quitkin, F. M.; Stewart, J. W.; McGrath, P. J.; Nunes, E.; Ocepek-Welikson, K.; Tricamo, E.; Rabkin, J. G.; Klein, D. F. Further evidence that a placebo response to antidepressants can be identified. Am. J. Psychiatry 1993, 150, 566-570.
64. Quitkin, F. M.; McGrath, P. J.; Rabkin, J. G.; Stewart, J. W.; Harrison, W.; Ross, D. C.; Tricamo, E.; Fleiss, J.; Markowitz, J.; Klein, D. F. Different types of placebo response in patients receiving antidepressants. Am. J. Psychiatry 1991, 148, 197-203.
65. Quitkin, F. M.; Rabkin, J. G.; Stewart, J. W.; McGrath, P. J.; Harrison, W.; Ross, D. C.; Tricamo, E.; Fleiss, J.; Markowitz, J.; Klein, D. F. Heterogeneity of clinical response during placebo treatment. Am. J. Psychiatry 1991, 148, 193-196.
66. Waugh, J.; Goa, K. L. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003, 17, 343-362.
67. Llorca, P. M.; Azorin, J. M.; Despiegel, N.; Verpillat, P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int. J. Clin. Pract. 2005, 59, 268-275.
68. Brannan, S. K.; Mallinckrodt, C. H.; Detke, M. J.; Watkin, J. G.; Tollefson, G. D. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J. Psychiatr. Res. 2005, 39, 161-172.
69. Rapaport, M. H.; Schneider, L. S.; Dunner, D. L.; Davies, J. T.; Pitts, C. D. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J. Clin. Psychiatry 2003, 64, 1065-1074.
70. Golden, R. N.; Nemeroff, C. B.; McSorley, P.; Pitts, C. D.; Dube, E. M. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin. Psychiatry 2002, 63, 577-584.
71. Montgomery, S.; Ferguson, J. M.; Schwartz, G. E. The antidepressant efficacy of reboxetine in patients with severe depression. J. Clin. Psychopharmacol. 2003, 23, 45-50.
72. Schneider, L. S.; Nelson, J. C.; Clary, C. M.; Newhouse, P.; Krishnan, K. R.; Shiovitz, T.; Weihs, K. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am. J. Psychiatry 2003, 160, 1277-1285.
73. Stahl, S. M.; Entsuah, R.; Rudolph, R. L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry 2002, 52, 1166-1174.
74. Holbrook, A.; Goldsmith, C. Innovation and placebos in research: a new design of clinical trial. Lancet 2003, 362, 2036-2037.